- |||||||||| ALTO-100 / Alto Neurosci
Phase classification: ALTO-100-201: Phase 2b Study of ALTO-100 in MDD (clinicaltrials.gov) - Jan 11, 2024
P2, N=266, Recruiting,
Based on these results, a prospective, biomarker-stratified, placebo-controlled phase 2b efficacy study is underway (NCT05712187). Phase classification: P2b --> P2
- |||||||||| ALTO-100 / Alto Neurosci
Alto-100 improves pattern separation in mice through a neurogenesis-dependent mechanism (WCC Halls A-C) - Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_10630;
Phase classification: P2b --> P2 We demonstrated that chronic pharmacological treatment with the compound ALTO-100 reliably improves context discrimination in non-irradiated mice, as we have previously shown.Furthermore, this effect appears to be neurogenesis-dependent, as X-irradiation and ablation of neurogenesis was able to block the effects of ALTO-100 on pattern separation.
- |||||||||| ALTO-100 / Alto Neurosci
Enrollment change, Trial completion date, Trial primary completion date: ALTO-100-201: Phase 2b Study of ALTO-100 in MDD (clinicaltrials.gov) - Oct 2, 2023
P2b, N=266, Recruiting,
We demonstrated that chronic pharmacological treatment with the compound ALTO-100 reliably improves context discrimination in non-irradiated mice, as we have previously shown.Furthermore, this effect appears to be neurogenesis-dependent, as X-irradiation and ablation of neurogenesis was able to block the effects of ALTO-100 on pattern separation. N=200 --> 266 | Trial completion date: Mar 2024 --> Sep 2024 | Trial primary completion date: Jan 2024 --> Aug 2024
- |||||||||| ALTO-100 / Alto Neurosci
A Pro-Neurogenic Compound, Alto-100, Improves Pattern Separation in Mice (Sapphire AB) - Apr 29, 2023 - Abstract #SOBP2023SOBP_943;
Histological measures of neurogenesis in these subjects will also be presented. Conclusions We observed that chronic treatment with Alto-100, a neurogenic compound, improved performance on a contextual fear discrimination task without having a notable effect on baseline contextual fear conditioning.
- |||||||||| ALTO-100 / Alto Neurosci
Trial completion, Enrollment change, Trial completion date: Pilot Decentralized Trial (clinicaltrials.gov) - Feb 9, 2023
P2, N=21, Completed,
Conclusions We observed that chronic treatment with Alto-100, a neurogenic compound, improved performance on a contextual fear discrimination task without having a notable effect on baseline contextual fear conditioning. Active, not recruiting --> Completed | N=50 --> 21 | Trial completion date: May 2023 --> Jan 2023
- |||||||||| ALTO-100 / Alto Neurosci
Trial completion: ALTO-100 in MDD and/or PTSD (clinicaltrials.gov) - Dec 21, 2022
P2, N=245, Completed,
Active, not recruiting --> Completed | N=50 --> 21 | Trial completion date: May 2023 --> Jan 2023 Active, not recruiting --> Completed
- |||||||||| ALTO-100 / Alto Neurosci
Enrollment closed, Enrollment change: Pilot Decentralized Trial (clinicaltrials.gov) - Oct 25, 2022
P2, N=50, Active, not recruiting,
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=225 --> 50
- |||||||||| ALTO-100 / Alto Neurosci
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: ALTO-100 in MDD and/or PTSD (clinicaltrials.gov) - Oct 21, 2022
P2, N=245, Active, not recruiting,
Recruiting --> Active, not recruiting | N=225 --> 50 Recruiting --> Active, not recruiting | N=350 --> 245 | Trial completion date: Jul 2023 --> Feb 2023 | Trial primary completion date: May 2023 --> Dec 2022
- |||||||||| ALTO-100 / Alto Neurosci
New P2 trial: Pilot Decentralized Trial (clinicaltrials.gov) - Jun 15, 2022
P2, N=225, Recruiting,
- |||||||||| ALTO-100 / Alto Neurosci
Enrollment open: ALTO-100 in MDD and/or PTSD (clinicaltrials.gov) - Jan 17, 2022
P2, N=350, Recruiting,
Recruiting --> Active, not recruiting | N=350 --> 245 | Trial completion date: Jul 2023 --> Feb 2023 | Trial primary completion date: May 2023 --> Dec 2022 Not yet recruiting --> Recruiting
- |||||||||| ALTO-100 / Alto Neurosci
New P2 trial: ALTO-100 in MDD and/or PTSD (clinicaltrials.gov) - Nov 10, 2021
P2, N=350, Not yet recruiting,
|
